
Prostate Cancer
Latest News
Latest Videos

CME Content
More News

Concomitant therapy with docetaxel and androgen deprivation therapy initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men who received ADT alone.

Neal D. Shore, MD, medical director, Carolina Urologic Research Center, managing partner, Atlantic Urology Clinics, discusses preliminary results of the Harris poll, which surveyed how men with advanced prostate cancer communicate with their practitioners.

New diagnoses of prostate cancer cases declined nearly 30% after the United States Preventive Services Task Force recommended against routine prostate-specific antigen screening for men.

Urologists who are in solo practice or not affiliated with a medical school may overuse primary gonadotropin-releasing hormone for men with localized prostate cancer.

Men with intermediate- or high-risk prostate cancer experienced higher survival rates when given increased radiation doses than men with low-risk disease.

Novel combination approaches are currently under exploration that hope to capitalize on the varying mechanisms of action for each newly approved agent for men with metastatic castration-resistant prostate cancer.

Edith Mitchell, MD, Prof of Medicine and Medical Oncology at Thomas Jefferson University, Director of the Center to Eliminate Cancer Disparities at the Sidney Kimmel Cancer Center at Thomas Jefferson University, discusses racial disparities in breast and prostate cancer.

Patients who were taking statins while also undergoing androgen deprivation therapy may experience a reduction in all-cause and prostate cancer-specific deaths.

Joe O'Sullivan, MD, discusses the efficacy of radium-223 when combined with enzalutamide and/or abiraterone in an international early access program for the treatment of patients with metastatic castration-resistant prostate cancer.

Charles J. Ryan, MD, discusses the final survival data for pre-chemotherapy use of abiraterone from the COUGAR-AA-302 study, which demonstrated a median of 35 months for men with castration resistant prostate cancer.

Xiaosong Meng, MD, PhD, NYU Langone Medical Center, discusses MRI-US fusion targeted biopsies and how they can be used to identify high-grade prostate cancers.

Lawrence Karsh, MD, FACS, director, Clinical Research Department, The Urology Center of Colorado, discusses the TERRAIN trial, which compared enzalutamide with bicalutamide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Neal Shore, MD, recently visited the OncLive News Network studios to discuss his role in LUGPA and provide his clinical insights about skeletal complications and the sequencing of radium-223.

A randomized study is underway to determine if the combination of sipuleucel-T (Provenge) and radium-223 (Xofigo) may improve outcomes in patients with metastatic castration-resistant prostate cancer.

Treating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures

Bone marrow failure may occur following treatment with radium-223 in a portion of patients with metastatic castration-resistant prostate cancer who have high skeletal tumor burden.

Dawn Hershman, MD, Associate Professor Medicine at Columbia University Medical Center, discusses the late-effects of intermittent androgen deprivation therapy (ADT) to continuous ADT in prostate cancer.

Nagi B. Kumar, PhD, Professor/Director, Cancer Chemoprevention, Moffitt Cancer Center, discusses the potential of green tea catechins for the prevention of prostate cancer.































































